Cerus Corp. Stock Rating Upgraded by McLean Capital Management (CERS)
Cerus Corp. (NASDAQ:CERS) was upgraded by research analysts at McLean Capital Management from a “sell” rating to a “neutral” rating in a report released on Friday, Analyst RN reports.
Shares of Cerus Corp. (NASDAQ:CERS) traded up 1.21% during mid-day trading on Friday, hitting $7.51. The stock had a trading volume of 859,199 shares. Cerus Corp. has a 52 week low of $3.13 and a 52 week high of $7.85. The stock’s 50-day moving average is $6.73 and its 200-day moving average is $6.21. The company’s market cap is $529.1 million.
Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.